1. Home
  2. MNMD vs CCAP Comparison

MNMD vs CCAP Comparison

Compare MNMD & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNMD
  • CCAP
  • Stock Information
  • Founded
  • MNMD 2019
  • CCAP 2015
  • Country
  • MNMD United States
  • CCAP United States
  • Employees
  • MNMD N/A
  • CCAP N/A
  • Industry
  • MNMD Pharmaceuticals and Biotechnology
  • CCAP Finance: Consumer Services
  • Sector
  • MNMD Health Care
  • CCAP Finance
  • Exchange
  • MNMD Nasdaq
  • CCAP Nasdaq
  • Market Cap
  • MNMD 559.5M
  • CCAP 637.1M
  • IPO Year
  • MNMD N/A
  • CCAP N/A
  • Fundamental
  • Price
  • MNMD $6.31
  • CCAP $16.82
  • Analyst Decision
  • MNMD Strong Buy
  • CCAP Strong Buy
  • Analyst Count
  • MNMD 9
  • CCAP 5
  • Target Price
  • MNMD $25.75
  • CCAP $19.20
  • AVG Volume (30 Days)
  • MNMD 2.5M
  • CCAP 180.4K
  • Earning Date
  • MNMD 03-06-2025
  • CCAP 05-07-2025
  • Dividend Yield
  • MNMD N/A
  • CCAP 1.19%
  • EPS Growth
  • MNMD N/A
  • CCAP N/A
  • EPS
  • MNMD N/A
  • CCAP 1.99
  • Revenue
  • MNMD N/A
  • CCAP $197,363,000.00
  • Revenue This Year
  • MNMD N/A
  • CCAP N/A
  • Revenue Next Year
  • MNMD N/A
  • CCAP N/A
  • P/E Ratio
  • MNMD N/A
  • CCAP $8.48
  • Revenue Growth
  • MNMD N/A
  • CCAP 7.18
  • 52 Week Low
  • MNMD $5.03
  • CCAP $16.81
  • 52 Week High
  • MNMD $12.22
  • CCAP $20.19
  • Technical
  • Relative Strength Index (RSI)
  • MNMD 41.01
  • CCAP 23.60
  • Support Level
  • MNMD $5.96
  • CCAP $16.81
  • Resistance Level
  • MNMD $6.77
  • CCAP $17.53
  • Average True Range (ATR)
  • MNMD 0.51
  • CCAP 0.43
  • MACD
  • MNMD -0.07
  • CCAP -0.13
  • Stochastic Oscillator
  • MNMD 27.31
  • CCAP 0.57

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.

About CCAP Crescent Capital BDC Inc. Common stock

Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.

Share on Social Networks: